Navigation Links
Lialda in Medical News

Long-term safety data on Lialda published in leading GI journal

Basingstoke, UK and Philadelphia, US June 17, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™...

New Analyses of long-term LIALDA (mesalamine) data presented at ACG

Philadelphia, PA October 15, 2007 Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate u...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

...nts who are newly prescribed or are already taking lialda or Pentasa and who become unemployed in 2009 can r...ar. In addition, more UC patients can benefit from lialda and Pentasa because Shire has raised the household...am (not valid in Mass.) and a 30-day free trial of lialda when patients join the...

Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease

...rapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyor...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...tudy were to assess the safety and tolerability of lialda in mild-to-moderate UC patients over 12 months. Da...terology. "This published data demonstrates that lialda is generally well tolerated and has a strong safet... the 303 study show that a majority of patients on lialda continued to remain in remission through 12 months...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...ith UC will develop colon cancer. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Nationwide survey reveals differing physician and patient perceptions regarding impact of UC

...tions on Remission Management and Lifestyle), were sponsored by Shire Pharmaceuticals, a specialty biopharmaceutical company, which markets once-daily lialda and PENTASA (mesalamines) for UC. Before these surveys, patient and physician views on UCs impact had not been compared and the real-life impact o...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...ssen the burden," said Dr. Rubin. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... 43.7 18% 2% 17% lialda 16.3 n/a n/a ...price increases in November 2006 and August 2007. lialda - Ulcerative colitis Shire launched lialda during March 2007. By September 30, 2007 LIALDA ha...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

..., NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug lialda (mesalamine) demonstrated a delivery system where ...erative colitis. In this in vitro model, after the lialda tablet passed through the simulated stomach, small...n adult GI tract, we were able to demonstrate that lialda tablets provide maximum release of 5-ASA in a prol...
Lialda in Medical Technology

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... of therapy for continuing patients, 20 percent of lialda patients were continually persistent, 9 percent of...tion of the prescription that preceded the refill. lialda is an FDA-approved, once-daily oral medication for...cerative colitis (UC). Safety and effectiveness of lialda beyond eight weeks have not been established. ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...om St Mark's Hospital in London, UK), demonstrated lialda was effective in inducing remission in patients wi... 8-week study. Patients in the Kamm study received lialda 2.4g/day once daily (n=84), 4.8g/day once daily (n... the definition used for remission, treatment with lialda 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...ug LIALDA(TM) (mesalamine) provide further data on lialda in patients with mild to moderate ulcerative colit...3 was safety and tolerability and findings -- that lialda is generally well tolerated in mild to moderate UC...tland in March 2007. "Earlier studies showed that lialda is well-tolerated and effective at inducing remiss...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

... people with UC will develop colon cancer. About lialda lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...
Lialda in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 4.9 n/a n/a n/a(5) n/a(5) lialda / MEZAVANT 54.6 71% 73% ... 54.0 44.8 21% 8% lialda / MEZAVANT 54.6 32.0 7... 105.2 89.0 18% 7% lialda / MEZAVANT 104.0 59.2 76...

Shire begins the year with a strong performance

...ncome within revenues. License agreement for lialda in Japan - On January 16, 2009 Shire announce...LDA(R) (mesalamine) in Japan. Termination of lialda co-promotion agreement - As of March 31, 2009...tical Products Inc., for the co-promotion of lialda in the US. Pipeline DAYTRANA - for the t...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... Pharmaceutical Co., Ltd to develop and sell lialda in Japan. - On February 9, 2009 Shire announc... 78.7 +23% -11% 1.8% lialda / MEZAVANT 140.4 +178% +204% ...er 31, 2008 (2007: 21.1%), driven by the growth of lialda since its launch in March 2007. LIALDA/MEZA...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... first time. The performance of ELAPRASE, VYVANSE, lialda and FOSRENOL ROW were particularly strong. This qu... 18.1 93% -14% 1.6% lialda / MEZAVANT 40.4 148% +143% ...er 30, 2008 (2007: 22.5%), driven by the growth of lialda since its launch in March 2007. The overall US ora...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...oduct sales comprise DAYTRANA, ELAPRASE, FOSRENOL, lialda / MEZAVANT and VYVANSE Angus Russell, Chief...Products Inc. ("TAP") commenced co-promotion of lialda in the US in accordance with the co-promotion a... 22.6 14% -11% 1.8% lialda / MEZAVANT 32.0 n/a n/a ...

Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards

...mpaigns." Cadient Group received the following Communicator Awards: -- lialda - Silver Communicator Award Cadient Group was recognized for its work with Shire US, Inc.'s lialda Web site, which offers information, tools, and resources for people ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...uency of our sales calls. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...VANT(R) - Ulcerative Colitis - By April 11, 2008 lialda had achieved a 9.8% share of the US oral mesalamin...hire's share of the US oral mesalamine market from lialda and PENTASA combined increased to 26.1% for the th...

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...of 120 representatives who are currently detailing lialda primarily to gastroenterologists. "Aligning with...mendous benefit for Shire as it will quadruple the lialda sales force across the United States," said Mike Y...th messages about Lialda. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...

Shire plc: IFRS Results for the Year Ending December 31, 2007

...LDA/MEZAVANT - Ulcerative colitis Shire launched lialda in the US oral mesalamine market in March 2007, and by December 31, 2007 lialda had reached a market share of 8.0% (average annual...were US$50.5 million. All initial launch stocks of lialda totaling US$34.3 million were recognised into reve...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...ertook three major new product launches - VYVANSE, lialda / MEZAVANT and DYNEPO - which have gone well and a...hire's share of the US oral mesalamine market from lialda and PENTASA(R) combined was 26.0% at February 8, 2... 176.4 +28% +3% 17.2% lialda 50.5 n/a n/a ...
Other Tags
(Date:7/28/2015)... ... July 28, 2015 , ... VAZATA, a ... expanding their cloud presence to support their rapidly growing business. , Headquarted in ... been serving the Dallas/Fort Worth area for almost 50 years. HeartPlace is recognized ...
(Date:7/28/2015)... ... 2015 , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... Avenue and Lies Road in Carol Stream. All are welcome. , Now in its ... and help to support individuals and families affected by a brain aneurysm. , “We ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... a number of publications, including Runner’s World Magazine, is plantar fasciitis . ... constant pain. , Designed by a professional athletic trainer, the Zensah Ankle ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named by ... of Value Added Resellers of ERP Software is a look at the firms that ... honor represents the second such award in 2015 for Intellitec Solutions, following being named ...
(Date:7/28/2015)... Saint Louis, MO (PRWEB) , ... July 28, 2015 , ... ... and back pain comes in as a close second. Clients suffering from headaches and ... help clients get started with chiropractic treatment, The Joint 's nine offices in ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
Other Contents